Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders.

Magen, Hila; Avigdor, Abraham; Nevo, Lee; Fried, Shalev; Gibori, Amit; Levin, Einav G; Lustig, Yaniv; Shkury, Eden; Rahav, Galia

Magen, Hila; Avigdor, Abraham; Nevo, Lee; Fried, Shalev; Gibori, Amit; Levin, Einav G; Lustig, Yaniv; Shkury, Eden; Rahav, Galia.

Afiliação

Magen H; Division of Hematology and Bone-Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Avigdor A; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Nevo L; Division of Hematology and Bone-Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Fried S; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Gibori A; Division of Hematology and Bone-Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Levin EG; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Lustig Y; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Shkury E; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Rahav G; The Infection Prevention and Control Unit, Sheba Medical Center, Ramat Gan, Israel.

PLoS One ; 18(5): e0284925, 2023.

Article em En | MEDLINE | ID: mdl-37126496

Assuntos

COVID-19; Paraproteinemias; Humanos; Anticorpos Neutralizantes; Vacina BNT162; Vacinas contra COVID-19; Plasmócitos; Imunoglobulina G; Anticorpos Antivirais; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google